1.
Drug Fights GLP-1 Muscle Loss; Unapproved Retatrutide Prescriptions; Protein Swap
(MedPage Today) -- Investigational apitegromab -- a selective myostatin activation inhibitor -- effectively preserved lean mass when combined with tirzepatide (Zepbound) in a randomized phase II trial, suggesting it could help fight "Ozempic...
2.
the bare minimum 013: mango jalapeño baked wings
No matter how you sauce them, this is a perfect base method to baking wings. Sauce it however you want; doesn’t affect my life.
5 pounds chicken wings, tips removed
1 teaspoon baking powder
1 teaspoon cornstarch
1 teaspoon salt
Preheat oven to 450°F, and place the oven rack on the middle level. I like to use convection, but not required.
While oven is heating, toss wings with baking powder, cornstarch, and salt.
3.
GSK Gets a Pair of Near-Commercial Lung Cancer Drugs via $10.6B Nuvalent Acquisition
GSK’s Nuvalent acquisition brings two lead programs, each addressing different targets for non-small cell lung cancer. The Nuvalent lung cancer drugs are under FDA review and if they’re approved, GSK plans to launch both this year.
The post GSK Gets a Pair of Near-Commercial Lung Cancer Drugs via $10.6B Nuvalent Acquisition appeared first on MedCity News.
4.
Low Lipoprotein(a) Harm; Soccer Pro Collapses Again; Cancer-Related Ischemic Stroke?
(MedPage Today) -- A low lipoprotein(a) level was tied to incident diabetes in the FOURIER trial. (European Heart Journal) People with 1.5 to 2 hours of strength training a week typically lived longer in a pooled cohort study.
5.
<a href="https://www.fiercepharma.com/pharma/gilead-trodelvy-stumbles-first-line-lung-cancer-all-eyes-merck-az-and-daiichi" hreflang="en">As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals</a>
Merck & Co. and Gilead are pulling the plug on the phase 3 Evoke-03 trial evaluating Trodelvy, combined with Keytruda, as a first-line treatment in patients with PD-L1-high non-small cell lung cancer.
6.
<a href="https://www.fiercepharma.com/pharma/wuxi-apptec-lands-us-government-list-companies-china-military-ties" hreflang="en">WuXi AppTec lands on Pentagon blacklist, facing Biosecure ban </a>
Inclusion on the Pentagon’s 1260H list automatically makes WuXi AppTec one of the “biotechnology companies of concern” under the Biosecure Act. WuXi AppTec maintains that its place on the list was "clearly a mistake," a spokesperson said.
7.
FDA Expands Sunscreen Options for the First Time in 20 Years
Today, the U.S. Food and Drug Administration added bemotrizinol to the list of permitted sunscreen active ingredients, marking a significant milestone in the agency's efforts to advance sunscreen innovation.
8.
Genomic Test May Spare More Patients With Node-Positive Breast Cancer From Chemo
(MedPage Today) -- The phase III OPTIMA trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, showed that some patients with high-risk, early-stage, estrogen receptor (ER)-positive, HER2-negative breast cancer...
9.
Oral Small-Molecule Elecoglipron Tackles Obesity and Diabetes
(MedPage Today) -- NEW ORLEANS -- Treatment with investigational elecoglipron led to weight loss in people with obesity and improved glucose control in those with type 2 diabetes, a pair of global phase II randomized trials showed.
10.
First Guideline on Cardiovascular-Kidney-Metabolic Syndrome Released
(MedPage Today) -- The first dedicated U.S. guideline for cardiovascular-kidney-metabolic (CKM) syndrome makes a big push to unite primary and specialty care in managing large swaths of the population. The American Heart Association (AHA) and...
